Literature DB >> 16673295

In vitro models for studying hepatitis B virus drug resistance.

Fabien Zoulim1.   

Abstract

Hepatitis B virus resistance to antivirals is conferred by the selection of polymerase gene mutants with reduced susceptibility to nucleoside analogues. Because of the increasing number of resistant mutants to the different available drugs, several phenotypic assays have been developed to provide cross-resistance data to guide clinicians in the management of therapy. Their possible use in the routine follow-up of antiviral treatment is also discussed. The different in vitro models for the study of HBV resistance include enzymatic and cell-based assays. Their relevance for the analysis of viral fitness, drug susceptibility, and cross-resistance is also reviewed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16673295     DOI: 10.1055/s-2006-939759

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  8 in total

1.  Current status of antiviral therapy for hepatitis B.

Authors:  Daryl T-Y Lau; Wissam Bleibel
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

Review 2.  Emerging drugs for hepatitis B.

Authors:  Fabien Zoulim
Journal:  Expert Opin Emerg Drugs       Date:  2007-05       Impact factor: 4.191

Review 3.  Antiviral drug resistance: mechanisms and clinical implications.

Authors:  Lynne Strasfeld; Sunwen Chou
Journal:  Infect Dis Clin North Am       Date:  2010-06       Impact factor: 5.982

4.  The HepaRG cell line: a valuable in vitro tool for hepatitis virus infection studies.

Authors:  Liesbeth Ceelen; Marusya Lieveld; Ramses Forsyth; Mathieu Vinken
Journal:  Hepatol Int       Date:  2013-02-14       Impact factor: 6.047

5.  Viral resistance in hepatitis B: prevalence and management.

Authors:  Fred Poordad; Grace M Chee
Journal:  Curr Gastroenterol Rep       Date:  2010-02

6.  HepSEQ: International Public Health Repository for Hepatitis B.

Authors:  Saravanamuttu Gnaneshan; Samreen Ijaz; Joanne Moran; Mary Ramsay; Jonathan Green
Journal:  Nucleic Acids Res       Date:  2006-11-27       Impact factor: 16.971

7.  rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus.

Authors:  Yan Liu; Zhihui Xu; Yan Wang; Xiaodong Li; Liming Liu; Li Chen; Shaojie Xin; Dongping Xu
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

8.  Establishment of stable cell lines in which the HBV genome replicates episomally for evaluation of antivirals.

Authors:  Suofeng Sun; Yuan Li; Bowei Liu; Bingyong Zhang; Shuangyin Han; Xiuling Li
Journal:  Arch Med Sci       Date:  2018-11-20       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.